Clinical Trial Update: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing coformulated favezelimab/pembrolizumab (MK-4280A) versus standard of care in previously treated metastatic PD-L1-positive colorectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Favezelimab (favezelimab)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-09-17